Kairos Pharma, LTD. entered into Binding Term Sheet with Celyn Therapeutics, Inc. valued at Asset acquisition of CL-273; consideration includes 16.5% fully diluted shares, $15 million mileston (effective 2026-03-02).
“On March 2, 2026, Kairos Pharma, Ltd., a Delaware corporation (the “Company”) entered into a binding term sheet with Celyn Therapeutics, Inc., a privately held biotechnology company (“Celyn”), regarding a proposed asset acquisition of CL-273 (the “Asset Acquisition”), an investigational, reversible, wild type sparing pan EGFR small molecule inhibitor being developed by Eilean Therapeutics for EGFR mutant non small cell lung cancer (the “Term Sheet”).”